CVR number 42224391
Industry 46.4610 Wholesale of pharmaceutical goods

GC Danmark ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2022/3
2022
2023/3
2023
2024/3
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 10.3% 14.4% 10.3%  
Credit score (0-100)  0 0 22 14 23  
Credit rating  N/A N/A BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
2022/3
2022
2023/3
2023
2024/3
Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 2,453 1,676 1,774  
EBITDA  0.0 0.0 230 178 172  
EBIT  0.0 0.0 230 178 172  
Pre-tax profit (PTP)  0.0 0.0 195.4 154.5 156.7  
Net earnings  0.0 0.0 146.1 117.0 127.7  
Pre-tax profit without non-rec. items  0.0 0.0 195 155 157  
 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
2022/3
2022
2023/3
2023
2024/3
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 186 229 302  
Interest-bearing liabilities  0.0 0.0 189 42.8 104  
Balance sheet total (assets)  0.0 0.0 799 504 642  
Net Debt  0.0 0.0 -327 -92.8 16.3  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2022/3
2022
2023/3
2023
2024/3
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 2,453 1,676 1,774  
Gross profit growth  0.0% 0.0% 0.0% -31.7% 5.8%  
Employees  0 0 3 2 2  
Employee growth %  0.0% 0.0% 0.0% -33.3% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 799 504 642  
Balance sheet change%  0.0% 0.0% 0.0% -36.9% 27.3%  
Added value  0.0 0.0 230.2 177.8 172.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 1.0 2.0 3.0  

Profitability 
2019
N/A
2020
N/A
2021
2022/3
2022
2023/3
2023
2024/3
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 9.4% 10.6% 9.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 28.8% 27.3% 30.1%  
ROI %  0.0% 0.0% 61.4% 55.0% 50.9%  
ROE %  0.0% 0.0% 78.5% 56.4% 48.1%  

Solidity 
2019
N/A
2020
N/A
2021
2022/3
2022
2023/3
2023
2024/3
Equity ratio %  0.0% 0.0% 23.3% 45.4% 47.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -142.2% -52.2% 9.5%  
Gearing %  0.0% 0.0% 101.7% 18.7% 34.4%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 36.8% 20.2% 21.7%  

Liquidity 
2019
N/A
2020
N/A
2021
2022/3
2022
2023/3
2023
2024/3
Quick Ratio  0.0 0.0 1.3 1.8 1.9  
Current Ratio  0.0 0.0 1.3 1.8 1.9  
Cash and cash equivalent  0.0 0.0 516.5 135.6 87.6  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2022/3
2022
2023/3
2023
2024/3
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 186.1 228.9 302.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2022/3
2022
2023/3
2023
2024/3
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 77 89 86  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 77 89 86  
EBIT / employee  0 0 77 89 86  
Net earnings / employee  0 0 49 58 64